Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
American Journal of Hematology|March 11, 2025
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and ManagementMithun Vinod Shah, Daniel A Arber, Devendra K Hiwase
Expert Review of Hematology|June 15, 2011
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patientsDevendra K Hiwase, David T Yeung, Deborah L White
International Journal of Molecular Sciences|February 24, 2024
Special Issue "Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms"Chung Hoow Kok, David T Yeung, Devendra K Hiwase
Immunological Reviews|December 17, 2014
Splice factor mutations and alternative splicing as drivers of hematopoietic malignancyChristopher N Hahn, Parvathy Venugopal, Hamish S Scott, et al.
Current Hematologic Malignancy Reports|August 20, 2022
Role of Germline Predisposition to Therapy-Related Myeloid NeoplasmsAnmol Baranwal, Christopher N Hahn, Mithun Vinod Shah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myelomaDevendra K Hiwase, Smita Hiwase, Michael Bailey, et al.
Blood Cancer Discovery|October 18, 2024
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant MicroenvironmentDeepak Singhal, Monika M Kutyna, Christopher N Hahn, et al.
International Journal of Hematology|May 27, 2017
Myeloid neoplasms with germline DDX41 mutationJesse J C Cheah, Christopher N Hahn, Devendra K Hiwase, et al.
Haematologica|October 16, 2012
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cellsDevendra K Hiwase, Verity A Saunders, Eva Nievergall, et al.
International Journal of Molecular Sciences|February 25, 2023
Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell LinesMonika M Kutyna, Sophie Loone, Verity A Saunders, et al.
Pageof 5